Cargando…
Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960786/ https://www.ncbi.nlm.nih.gov/pubmed/35347180 http://dx.doi.org/10.1038/s41598-022-09081-4 |
| _version_ | 1784677454167670784 |
|---|---|
| author | Li, Maohua Zhao, Rongqing Chen, Jianxin Tian, Wenzhi Xia, Chenxi Liu, Xudong Li, Yingzi Li, Song Sun, Hunter Shen, Tong Ren, Wenlin Sun, Le |
| author_facet | Li, Maohua Zhao, Rongqing Chen, Jianxin Tian, Wenzhi Xia, Chenxi Liu, Xudong Li, Yingzi Li, Song Sun, Hunter Shen, Tong Ren, Wenlin Sun, Le |
| author_sort | Li, Maohua |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8960786 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89607862022-03-30 Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo Li, Maohua Zhao, Rongqing Chen, Jianxin Tian, Wenzhi Xia, Chenxi Liu, Xudong Li, Yingzi Li, Song Sun, Hunter Shen, Tong Ren, Wenlin Sun, Le Sci Rep Author Correction Nature Publishing Group UK 2022-03-28 /pmc/articles/PMC8960786/ /pubmed/35347180 http://dx.doi.org/10.1038/s41598-022-09081-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Li, Maohua Zhao, Rongqing Chen, Jianxin Tian, Wenzhi Xia, Chenxi Liu, Xudong Li, Yingzi Li, Song Sun, Hunter Shen, Tong Ren, Wenlin Sun, Le Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo |
| title | Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo |
| title_full | Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo |
| title_fullStr | Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo |
| title_full_unstemmed | Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo |
| title_short | Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo |
| title_sort | author correction: next generation of anti-pd-l1 atezolizumab with enhanced anti-tumor efficacy in vivo |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960786/ https://www.ncbi.nlm.nih.gov/pubmed/35347180 http://dx.doi.org/10.1038/s41598-022-09081-4 |
| work_keys_str_mv | AT limaohua authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT zhaorongqing authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT chenjianxin authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT tianwenzhi authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT xiachenxi authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT liuxudong authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT liyingzi authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT lisong authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT sunhunter authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT shentong authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT renwenlin authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo AT sunle authorcorrectionnextgenerationofantipdl1atezolizumabwithenhancedantitumorefficacyinvivo |